Financial Analysis: Guided Therapeutics (GTHP) vs. Its Peers

Guided Therapeutics (OTCMKTS:GTHP) is one of 70 public companies in the “Electromedical equipment” industry, but how does it weigh in compared to its competitors? We will compare Guided Therapeutics to similar businesses based on the strength of its dividends, risk, valuation, profitability, earnings, institutional ownership and analyst recommendations.

Profitability

This table compares Guided Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-350.61%	-97.06%	-31.48%

Risk & Volatility

Guided Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ competitors have a beta of 0.88, indicating that their average stock price is 12% less volatile than the S&P 500.

Institutional and Insider Ownership

9.7% of Guided Therapeutics shares are held by institutional investors. Comparatively, 44.2% of shares of all “Electromedical equipment” companies are held by institutional investors. 66.8% of Guided Therapeutics shares are held by company insiders. Comparatively, 13.9% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Guided Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Guided Therapeutics Competitors	259	780	1923	59	2.59

As a group, “Electromedical equipment” companies have a potential upside of 3,163.72%. Given Guided Therapeutics’ competitors higher possible upside, analysts plainly believe Guided Therapeutics has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Guided Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-5.58
Guided Therapeutics Competitors	$1.06 billion	$91.09 million	87.01

Guided Therapeutics’ competitors have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Guided Therapeutics competitors beat Guided Therapeutics on 7 of the 10 factors compared.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.